Presently, digital rectal examination (DRE) [4], transrectal ultrasound (TRUS) [5], magnetic resonance imaging (MRI) [6,7,8], and prostate-specific antigen (PSA) testing [9,10] are the primary diagnostic modalities for clinical identification of prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.